Streptococcus (e.g., Group B Streptococcus, Pneumococcus Or Streptococcus Pneumoniae, Etc.) Patents (Class 424/244.1)
-
Publication number: 20140287043Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.Type: ApplicationFiled: April 23, 2012Publication date: September 25, 2014Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Fiorenzo Omenetto
-
Patent number: 8828409Abstract: A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein of S. pneumoniae in an immunologically effective amount to the human or animal.Type: GrantFiled: November 24, 2010Date of Patent: September 9, 2014Assignees: Sungkyunkwan University, Adelaide Research & Innovation Pty Ltd.Inventors: Dong-Kwon Rhee, Hyeok-Young Kwon, Mu-Hyeon Choi, Abiodun David Ogunniyi, James Cleland Paton
-
Patent number: 8821895Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: October 24, 2012Date of Patent: September 2, 2014Assignee: ID Biomedical Corporation of QuebecInventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Patent number: 8815254Abstract: The present invention relates to a method of detoxifying bacterial cytolysins such as pneumococcal pneumolysin, utilizing chemical cross-linking compounds.Type: GrantFiled: September 27, 2012Date of Patent: August 26, 2014Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Ralph Biemans, Karine Goraj, Emmanuel Mertens, Annick Vandercammen
-
Patent number: 8808704Abstract: The embodiments described herein provide for immunogenic portions of Streptococcus pneumoniae surface protein A and surface protein C lacking alpha helical structure.Type: GrantFiled: February 1, 2007Date of Patent: August 19, 2014Assignee: The UAB Research FoundationInventors: Susan K. Hollingshead, David E. Briles
-
Publication number: 20140220065Abstract: A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcusType: ApplicationFiled: February 3, 2014Publication date: August 7, 2014Inventors: LUIZA GUILHERME GUGLIELMI, JORGE ELIAS KALIL FILHO
-
Patent number: 8795690Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.Type: GrantFiled: November 26, 2012Date of Patent: August 5, 2014Assignee: Valneva Austria GmbHInventors: Beatrice Tschanun, Eszter Nagy, Andreas Meinke, Alexander Von Gabain, Barbara Maierhofer, Ulrike Stierschneider, Manfred Berger, Christina Neubauer, Katherine Cohen
-
Patent number: 8795689Abstract: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae 19A capsular polysaccharides. In certain methods, a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 19A capsular polysaccharides is fermented for less than 6 hours before the bacterial cells are lysed the capsular polysaccharides are harvested. In other methods, CO2 is supplied to the fermentation culture. Supplying CO2 to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO2.Type: GrantFiled: December 17, 2009Date of Patent: August 5, 2014Assignee: Wyeth LLCInventor: Jean Heather Crinean
-
Patent number: 8790658Abstract: Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous compositions. Also disclosed are devices for administering the vitreous compositions to mammals and methods for eliciting an immune response in mammals by administering the compositions.Type: GrantFiled: July 25, 2008Date of Patent: July 29, 2014Assignee: Sanofi Pasteur LimitedInventors: Sandrine Cigarini, Kevin Harper, Manvi Hasija
-
Publication number: 20140205634Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.Type: ApplicationFiled: February 10, 2014Publication date: July 24, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe DENOEL, Philippe Vincent HERMAND, Steve LABBE, Jan POOLMAN, Stephane RIOUX
-
Patent number: 8778358Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.Type: GrantFiled: October 18, 2010Date of Patent: July 15, 2014Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Cira Daniela Rinaudo, Domenico Maione
-
Publication number: 20140193461Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species of the genus Streptococcus (e.g., Streptococcus pneumoniae))). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Paul E. Makidon, Whitney A. Dunlap, Jessica A. Knowlton, Benjamin Swanson
-
Publication number: 20140186399Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicant: President and Fellows of Harvard CollegeInventor: John J. MEKALANOS
-
Patent number: 8753649Abstract: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.Type: GrantFiled: May 10, 2013Date of Patent: June 17, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Che-Hung Robert Lee, Carl E. Frasch
-
Publication number: 20140161836Abstract: The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S. mutans and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by S. mutans by administrating to a subject the vaccine composition.Type: ApplicationFiled: December 29, 2011Publication date: June 12, 2014Applicant: WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCESInventors: Huimin Yan, Wei Shi, Ying Sun, Jingyi Yang
-
Publication number: 20140141041Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).Type: ApplicationFiled: December 30, 2013Publication date: May 22, 2014Applicant: VAXIN INC.Inventor: De-Chu C. Tang
-
Patent number: 8728490Abstract: Described are Streptococcus suis infections in pigs, vaccines directed against those infections and tests for diagnosing S. suis infections. Provided is an isolated or recombinant nucleic acid encoding a capsular gene cluster of S. suis or a gene or gene fragment derived therefrom. Further provided is a nucleic acid probe or primer allowing species or serotype-specific detection of S. suis. Also provided is a Streptococcus suis antigen and vaccine derived therefrom.Type: GrantFiled: June 16, 2010Date of Patent: May 20, 2014Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith
-
Patent number: 8722055Abstract: Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R2i or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope.Type: GrantFiled: September 26, 2007Date of Patent: May 13, 2014Assignee: St. Jude Children's Research HospitalInventors: Karim C. El Kasmi, Brad Jordan, Richard Kriwacki, Beth Mann, Carlos J. Orihuela, Elaine Tuomanen
-
Publication number: 20140127263Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicant: OmniGen Research, L.L.C.Inventors: Neil E. Forsberg, Steven B. Puntenney
-
Patent number: 8709438Abstract: The present invention relates to a vaccine composition against Streptococcus pyogenes infection comprising an amino acid sequence having C-terminal fragment of streptococcal pyrogenic exotoxin B, and a pharmaceutical acceptable adjuvant.Type: GrantFiled: July 11, 2012Date of Patent: April 29, 2014Assignee: I-Shou UniversityInventors: Chih-Feng Kuo, Nina Tsao
-
Publication number: 20140105927Abstract: The present invention relates to an immunogenic composition comprising (i) at least one Streptococcus pneumoniae protein; (ii) a Streptococcus pneumoniae capsular saccharide derived from a strain of a targeted serotype of Streptococcus pneumoniae; for use in enhancing antibody-mediated opsonic activity against the targeted serotype of Streptococcus pneumoniae.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: GlaxoSmithKline Biologicals S.A.Inventor: VINCENT VERLANT
-
Patent number: 8697085Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.Type: GrantFiled: June 15, 2012Date of Patent: April 15, 2014Assignee: University of Tennessee Research FoundationInventor: James B. Dale
-
Publication number: 20140099339Abstract: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Hermand, Craig A. J. Laferriere, Yves Lobet, Jan Poolman
-
Patent number: 8691243Abstract: Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more Streptococcus pneumoniae cell wall and/or cell membrane proteins and/or immunogenically-active fragments, derivatives or modifications thereof, wherein the proteins are selected from a defined group of proteins associated with age-dependent immunological responses.Type: GrantFiled: January 4, 2013Date of Patent: April 8, 2014Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventor: Yaffa Mizrachi Nebenzahl
-
Publication number: 20140086989Abstract: The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.Type: ApplicationFiled: May 15, 2012Publication date: March 27, 2014Applicant: Matrivax, Inc.Inventors: Kevin P. Killeen, Robert T. Cartee
-
Publication number: 20140072622Abstract: The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated Streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the Polyhistidine Triad family (e.g. PhtD), which comprise adjuvants comprising QS21 and monophosphoryl lipid A (MPL), and are presented in the form of a liposome.Type: ApplicationFiled: May 15, 2012Publication date: March 13, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Denoel, Jan Poolman, Vincent Verlant, Hugues Wallemacq
-
Patent number: 8668911Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species of the genus Streptococcus (e.g., Streptococcus pneumoniae))). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: GrantFiled: May 14, 2010Date of Patent: March 11, 2014Assignee: The Regents Of The University Of MichiganInventors: James R. Baker, Jr., Paul E. Makidon, Whitney A. Dunlap, Jessica A. Knowlton, Benjamin Swanson
-
Patent number: 8663655Abstract: The present invention relates to peptides, nucleic acids and methods for transforming a bacterium belonging to the Streptococcus genus by natural competence and their use in the food and feed industry.Type: GrantFiled: June 23, 2010Date of Patent: March 4, 2014Assignee: Dupont Nutrition Biosciences APSInventors: Patrick Boyaval, Christophe Fremaux, Pascal Hols, Laetitia Fontaine, Philippe Horvath
-
Publication number: 20140056944Abstract: The present invention includes a method and device for the isolation of lymphocytes, particularly splenic lymphocytes, for administration to patients. In particular for patients undergoing a splenectomy, administration of splenic lymphocytes may increase a patient's immunity and reduce the likelihood of post-splenectomy infections and other complications.Type: ApplicationFiled: August 22, 2013Publication date: February 27, 2014Applicant: Children's Hospital of Orange CountyInventor: Mustafa Kabeer
-
Publication number: 20140050732Abstract: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.Type: ApplicationFiled: March 15, 2013Publication date: February 20, 2014Inventors: Fabrice Bureau, Hughes Wallemacq, Philippe Boutet, Pierre Lekeux, Laurence Fievez, Julien Pujol
-
Publication number: 20140044734Abstract: The invention is in the field of prevention and medical treatment of liver diseases, in particular non-alcoholic steatohepatitis (NASH). The invention provides means and methods for the treatment of hepatic inflammation, fibrosis and more in particular NASH. More in particular, the invention provides a composition capable of raising anti-oxLDL antibodies in vivo for use in the treatment of liver inflammation or fibrosis.Type: ApplicationFiled: February 21, 2012Publication date: February 13, 2014Inventors: Ronit Sverdlov, Veerle Bieghs, Patrick Johannes Jacobus van Gorp
-
Publication number: 20140037688Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.Type: ApplicationFiled: November 4, 2011Publication date: February 6, 2014Applicant: QUORUM INNOVATIONS, LLCInventors: Eva A. Berkes, Nicholas T. Monsul
-
Publication number: 20140037716Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.Type: ApplicationFiled: March 19, 2012Publication date: February 6, 2014Inventor: Alexandre Eduardo Nowill
-
Patent number: 8642048Abstract: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention.Type: GrantFiled: January 27, 2009Date of Patent: February 4, 2014Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Scott E. Johnson, Danny L. Jue, Jacquelyn S. Sampson, George M. Carlone
-
Patent number: 8642049Abstract: VACCIN AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF, which predicts the production of recombinant protein cloned from the gene emm5, which contains a sequence of oligonucleotides corresponding to 52 and/or 87 amino acid residues capable of protection, isolated after the sequential molecular identification of the epitopes from the M protein carboxy-terminal region, differing in 01 amino acid residue, identified by antibodies and T lymphocytes of health human beings and of patients carriers of rheumatic fever, capable of generating a protective response by antibodies depending on the T lymphocytes; prevention of the development of the autoimmune disease by the selected epitope was evaluated in vitro with T lymphocytes from the cardiac tissue of patients with lesions arising out of rheumatic fever.Type: GrantFiled: July 19, 2007Date of Patent: February 4, 2014Inventors: Luiza Guilherme Guglielmi, Jorge Elias Kalil Filho
-
Patent number: 8642042Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.Type: GrantFiled: August 7, 2007Date of Patent: February 4, 2014Assignee: President and Fellows of Harvard CollegeInventor: John J. Mekalanos
-
Patent number: 8637050Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies.Type: GrantFiled: March 18, 2013Date of Patent: January 28, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Bernard W. Beall, George M. Carlone, Jacquelyn S. Sampson, Edwin W. Ades
-
Patent number: 8637049Abstract: Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture.Type: GrantFiled: April 6, 2011Date of Patent: January 28, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Yuping Wei Pridgeon, Phillip H. Klesius
-
Patent number: 8632784Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.Type: GrantFiled: June 7, 2006Date of Patent: January 21, 2014Assignee: Sanofi Pasteur LimitedInventors: Richard William Falla Le Page, Jeremy Mark Wells, Sean Bosco Hanniffy, Philip Michael Hansbro
-
Patent number: 8628766Abstract: The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising from Streptococcus suis bacteria of a serotype other than the predetermined one. The invention also pertains to Streptococcus suis antigens for use in the manufacture of such a vaccine.Type: GrantFiled: March 25, 2010Date of Patent: January 14, 2014Assignee: Intervet International B.V.Inventors: Henricus Leo Bernardus Maria Klaasen, Ruud Philip Antoon Maria Segers
-
Publication number: 20140004144Abstract: The present invention provides attenuated S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations in S. suis genes, which are useful in the production of novel attenuated S. suis bacterial strains.Type: ApplicationFiled: June 24, 2013Publication date: January 2, 2014Applicant: MERIAL LIMITEDInventors: Russell F Bey, Paulraj Kirubakaran Lawrence, Randy R Simonson, Kamesh Reddy Sirigireddy, Danielle A McKeown
-
Patent number: 8609107Abstract: The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: September 13, 2012Date of Patent: December 17, 2013Assignee: Sanofi Pasteur LimitedInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Publication number: 20130315958Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.Type: ApplicationFiled: May 9, 2013Publication date: November 28, 2013Inventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
-
Patent number: 8563001Abstract: A number of ?-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by ?-hemolytic streptococci.Type: GrantFiled: November 4, 2009Date of Patent: October 22, 2013Assignee: Regents of the University of MinnesotaInventors: Ingrid Lea Dodge, Annaliesa Sybil Anderson, Michael Hagen, Stephen Bruce Olmsted
-
Publication number: 20130259948Abstract: The present invention relates to a novel effective dry powder vaccine formulation that increases the immune response in the host. The formulation comprises of an antigen entrapped into a polymer particle, coated with alum, finally spray dried into a dry powder. This formulation is used to elicit long lasting higher antibody titers than alum adsorbed antigen or admixture of polymer entrapped antigen and alum.Type: ApplicationFiled: September 20, 2011Publication date: October 3, 2013Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Amulya Kumar Panda, Anish Chakkunkal, Dinesh Giri Goswami
-
Publication number: 20130243818Abstract: The present invention provides an immunogenic composition comprising one or more Streptococcus uberis proteins, or an immunogenic part thereof, wherein the composition is capable of eliciting an immune response, when administered to a subject.Type: ApplicationFiled: March 1, 2013Publication date: September 19, 2013Applicant: The University of NottinghamInventor: James Leigh
-
Publication number: 20130236469Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: May 25, 2011Publication date: September 12, 2013Applicant: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 8529913Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: March 2, 2012Date of Patent: September 10, 2013Assignee: Novartis Vaccines and Diagnostics, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Patent number: 8529911Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.Type: GrantFiled: July 6, 2007Date of Patent: September 10, 2013Assignee: Intercell Austria AGInventors: Andreas Meinke, Eszter Nagy, Alexander von Gabain, Manfred Berger, Beatrice Senn, Michael Schunn
-
Patent number: RE45170Abstract: The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.Type: GrantFiled: August 30, 2013Date of Patent: September 30, 2014Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith